Business Wire

AGC Completes Third-Party Verification Under UL 2809 for Fluorine Raw Materials Used in AFLAS™ FFKM

29.5.2026 04:00:00 CEST | Business Wire | Press Release

Share

AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the industry-leading levels*5 of recycled material utilization in fluoroelastomer materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528992272/en/

Environmental Claim Validation labels for the three AFLAS™ FFKM product lines

AFLAS™ FFKM is an industrial elastomer that offers one of the highest levels of chemical resistance, heat resistance, and plasma resistance among fluorinated elastomers, and is used in a wide range of applications, particularly in the semiconductor manufacturing sector. Its resistance to degradation under harsh conditions makes it suitable for use in sealing materials and O-rings in applications requiring high reliability and durability.

The AGC Group has been working to recycle waste generated at its own plants and utilize it in fluorine products as Recycled Circular Fluorite. In 2025, the AGC Group was the first in the world to complete third-party verification based on UL 2809 for Fluon™ PTFE. With the completion of this verification, the AGC Group has prepared to offer AFLAS™ FFKM as a product that successfully combines high performance with environmental considerations.
After completing this verification, the AGC Group is ready to introduce AFLAS™ FFKM, a product that blends exceptional performance with environmental awareness.

Under its mid-term management plan AGC plus-2026, the AGC Group identifies “Deepening of Sustainability Management” as one of its key strategies. The Group will continue to actively work toward the realization of a circular economy for fluorine resources.

Notes

*1

This involves a third-party organization verifying the actual use of Recycled Circular Fluorite and evaluating whether the management of raw material credits complies with the relevant regulations based on the mass balance approach specified in UL 2809.

*2

UL 2809 (ECV: Environmental Claim Validation): A standard for verifying the content of recycled materials in a product by evaluating it in accordance with the environmental performance verification procedure for recycled material content established by UL Solutions, Inc. in the United States.

*3

A method used when manufacturing by blending raw materials with different properties (e.g., Recycled Circular Fluorite and mined fluorite), whereby the properties of the recycled raw materials are “allocated” to a portion of the final product in proportion to the percentage of recycled material used. For example, if 20% Recycled Circular Fluorite is used in the overall manufacturing process, up to 20% of the final product may be designated as “100% Recycled Circular Fluorite”, while the remaining 80% is treated as “0%.”

*4

In the chemical composition of AFLAS™ FFKM polymer grades, fluorine atoms account for approximately 73 wt% of the total composition. Based on the mass balance approach, AGC manages the raw materials for this fluorine component such that 100 wt% is derived from recycled materials. The remainder of the composition consists primarily of carbon.

*5

Based on AGC’s research (as of May 2026)

Reference

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528992272/en/

Contacts

Media inquiries
AGC Inc.
Corporate Communications & Investor Relations Division Contact form -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcontact.agc.co
m%2Fwebapp%2Fform%2F17985_tpab_181%2Findex.do&esheet=54542308&newsitemid=2026052
8992272&lan=en-US&anchor=Contact+form&index=6&md5=b4a0a180ff6437d9090fefdda299fd
66
https://www.agc.com/en/contact/index.html -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.agc.com%2F
en%2Fcontact%2Findex.html&esheet=54542308&newsitemid=20260528992272&lan=en-US&an
chor=https%3A%2F%2Fwww.agc.com%2Fen%2Fcontact%2Findex.html&index=7&md5=9dd1194c1
f59ae4a492d0d3abea34b9f

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye